Matinas BioPharma Holdings, Inc. experienced a substantial reduction in net loss for the first quarter of 2025, reporting a net loss of $1.656 million compared to $5.824 million in the same period last year. This improvement was primarily due to a decrease in total costs and expenses, particularly in research and development, as the company paused its MAT2203 development program and implemented cost-cutting measures.

Matinas BioPharma reported no revenue for Q2 2024, with a net loss of $5.7 million, slightly improved from $6.1 million in Q2 2023. The company is actively pursuing partnership opportunities for MAT2203 and signed a non-binding term sheet for global licensing rights.

Matinas BioPharma reported no revenue for the first quarter of 2024, with a net loss of $5.8 million, or $0.03 per share. The company's cash, cash equivalents, and marketable securities totaled $8.1 million as of March 31, 2024, and a subsequent financing of $10.0 million is expected to fund operations into the second quarter of 2025. The company remains on track with partnership discussions to advance oral MAT2203 into the ORALTO trial.

Matinas BioPharma reported revenue of $1.1 million for 2023, primarily from research collaborations. The company's net loss for the year was $22.9 million, or $0.11 per share. Cash, cash equivalents, and marketable securities totaled $13.8 million as of December 31, 2023, expected to fund operations through Q3 2024.

Matinas BioPharma reported no revenue for Q3 2023 compared to $1.1 million in Q3 2022. Total costs and expenses were $6.1 million, down from $6.5 million in the prior year. The net loss was $6.1 million, or $0.03 per share, compared to a net loss of $5.5 million, or $0.03 per share, in Q3 2022. Cash, cash equivalents and marketable securities were $18.2 million as of September 30, 2023.

Matinas BioPharma reported no revenue for the second quarter of 2023 compared to $1.1 million in Q2 2022. Total costs and expenses for the second quarter of 2023 were $6.2 million compared to $7.0 million for the second quarter of 2022. The net loss for the second quarter of 2023 was $6.1 million, or $0.03 per share, compared to a net loss for the second quarter of 2022 of $5.9 million, or $0.03 per share. Cash, cash equivalents and marketable securities as of June 30, 2023 were $22.5 million.

Matinas BioPharma reported a net loss for Q1 2023, with ongoing focus on advancing their pipeline, including MAT2203 and MAT2025. The company highlighted its financial stability with sufficient cash reserves to support operations into the second quarter of 2024.

Matinas BioPharma reported revenue of $3.2 million for the year ended December 31, 2022, primarily from the BioNTech SE collaboration. The net loss attributable to common shareholders for 2022 was $21.0 million, or $0.10 per share. Cash, cash equivalents, and marketable securities as of December 31, 2022, were $28.8 million, expected to fund operations into the second quarter of 2024.

Matinas BioPharma reported a net loss of $5.5 million for the third quarter of 2022. The company's cash, cash equivalents, and marketable securities were $33.1 million as of September 30, 2022, which is expected to fund operations through 2023. Key highlights include the successful completion of Phase 2 for MAT2203 and preparation for Phase 3.

Matinas BioPharma reported a net loss attributable to common shareholders of $5.9 million, or $0.03 per share, for the second quarter of 2022. The company's cash, cash equivalents, and marketable securities were approximately $38.5 million as of June 30, 2022, which is expected to fund planned operations through 2023.

Matinas BioPharma reported a net loss attributable to common shareholders of $6.0 million, or $0.03 per share, for the first quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $43.9 million as of March 31, 2022, which is expected to fund operations through 2023.

Matinas BioPharma reported a net loss attributable to common shareholders of $6.7 million, or a net loss of $0.03 per share for the fourth quarter of 2021. The company's cash, cash equivalents and marketable securities were approximately $49.6 million at the end of the year, which is expected to fund planned operations through 2023.

Matinas BioPharma reported a net loss of $6.8 million for the third quarter of 2021. The company's cash, cash equivalents, and marketable securities were approximately $53.8 million as of September 30, 2021, sufficient to fund planned operations into 2024. Significant pipeline progress was achieved, including advancement to the second half of the EnACT study and initiation of a Phase 1 study with MAT2501.

Matinas BioPharma reported a net loss of $5.0 million for the second quarter of 2021, with cash, cash equivalents, and marketable securities totaling $59.8 million as of June 30, 2021. The company believes its cash on hand is sufficient to fund operations into 2024. Enrollment was completed in the second cohort of the EnACT study of MAT2203, and positive FDA feedback was received on the MAT2501 development program.

Matinas BioPharma reported a net loss attributable to common shareholders of $5.2 million, or a net loss of $0.03 per share for the first quarter of 2021. Cash, cash equivalents and marketable securities were approximately $60.7 million at March 31, 2021.

Matinas BioPharma reported a net loss attributable to common shareholders of $6.6 million, or a net loss of $0.03 per share for the fourth quarter of 2020. The company's cash, cash equivalents and marketable securities were approximately $58.7 million as of December 31, 2020.

Matinas BioPharma reported a net loss attributable to common shareholders of $5.7 million, or $0.03 per share, for the third quarter of 2020. The company's cash, cash equivalents, and marketable securities were approximately $62.8 million as of September 30, 2020.

Matinas BioPharma announced that the ENHANCE-IT study of MAT9001 and the EnACT study of MAT2203 have resumed rapid enrollment after a temporary pause due to the COVID-19 pandemic. The company expects potential cohort progression in EnACT in the fourth quarter of this year and topline data from ENHANCE-IT in the first quarter of 2021.

Matinas BioPharma reported a net loss attributable to common shareholders of $5.2 million, or a net loss per share of $0.03 for the first quarter of 2020. The company's cash, cash equivalents, and marketable securities were approximately $71.2 million as of March 31, 2020, sufficient to fund operations into the first half of 2023.

Matinas BioPharma reported a net loss attributable to common shareholders of $5.8 million for the fourth quarter of 2019. The company's cash, cash equivalents and marketable securities were approximately $27.8 million as of December 31, 2019. They initiated the ENHANCE-IT study of MAT9001 against Vascepa and the efficacy phase of the NIH-funded EnACT study of MAT2203.